The European health authorities have approved a new label for diabetic drug Galvus, according to manufacturer Novartis AG. The drug is on the way to a European launch.
Novartis, a Swiss pharmaceutical company, will start to sell the drug to patients over the course of 2008. The European Committee for Medicinal Products had previously recommended that the label be approved .
The drug for diabetics is faring somewhat differently in American, where the Food and Drug Administration have delayed the approval since February 2007.
The chief executive of Novartis, Daniel Vasella, reportedly commented: “As long was we do not have a programme of which we are confident that we will get approval, we will not start a fresh filing process.”
Galvus is part of a new group of diabetic drugs.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…